Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/Microrna-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity

Journal of Biological Chemistry

Volumn 290, Issue 2, 2015, Pages 1170-1185

  Wu, Qian ^a   Liu, Hai Ou ^a   Liu, Yi Dong ^a   Liu, Wei Si ^a   Pan, Deng ^a   Zhang, Wei Juan ^b   Yang, Liu ^a   Fu, Qiang ^a   Xu, Jie Jie ^a   Gu, Jian Xin ^a  

^a BEIJING HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CELLS; CHEMICAL ACTIVATION; CYTOLOGY; DIAGNOSIS; MAMMALS; RNA; TRANSCRIPTION; TUMORS; VIRUSES;

CHROMATIN IMMUNOPRECIPITATION ASSAY; EPIDERMAL GROWTH FACTOR RECEPTORS; GLYCOSYL TRANSFERASE; HEPATOCARCINOGENESIS; HEPATOCELLULAR CARCINOMA; HEPATOCYTE NUCLEAR FACTORS; PROLIFERATION AND APOPTOSIS; TRANSCRIPTIONAL REGULATION;

GENE EXPRESSION;

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MICRORNA 122; N ACETYLGALACTOSAMINYLTRANSFERASE; N ACETYLGALACTOSAMINYLTRANSFERASE 10; SORAFENIB; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; MICRORNA; MIRN122 MICRORNA, HUMAN; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENICITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA TUMOR VIRUS; DOWN REGULATION; DRUG RECHALLENGE; DRUG SENSITIVITY; FEMALE; GALNT10 GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; GENE SILENCING; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS ASSOCIATED HEPATOCELLULAR CARCINOMA; HNF4ALPHA GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; OVERALL SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; RNA GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR INVASION; BIOSYNTHESIS; CARCINOGENESIS; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; PATHOGENICITY; PATHOLOGY; PROMOTER REGION; VIROLOGY;

HEPATITIS B VIRUS; MAMMALIA;

CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATITIS B VIRUS; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; LIVER NEOPLASMS; MICRORNAS; N-ACETYLGALACTOSAMINYLTRANSFERASES; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84920895787     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.601203     Document Type: Article

References (75)

1. Maluccio, M., and Covey, A. (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J. Clin. 62, 394-399
2. El-Serag, H. B., and Mason, A. C. (1999) Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745-750
3. Farazi, P. A., and DePinho, R. A. (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687
4. Li, C., Tan, Y. X., Zhou, H., Ding, S. J., Li, S. J., Ma, D. J., Man, X. B., Hong, Y., Zhang, L., Li, L., Xia, Q. C., Wu, J. R., Wang, H. Y., and Zeng, R. (2005) Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: identification of potential tumor markers. Proteomics 5, 1125-1139
5. Okabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y., and Nakamura, Y. (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61, 2129-2137
6. Hakomori, S. (1985) Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res. 45, 2405-2414
7. Blomme, B., Van Steenkiste, C., Callewaert, N., and Van Vlierberghe, H. (2009) Alteration of protein glycosylation in liver diseases. J. Hepatol. 50, 592-603
8. Dennis, J. W., Granovsky, M., and Warren, C. E. (1999) Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473, 21-34
9. Fuster, M. M., and Esko, J. D. (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526-542
10. Fukuda, M. (1996) Possible roles of tumor-associated carbohydrate antigens. Cancer Res. 56, 2237-2244
11. Dennis, J. W., Laferté, S., Waghorne, C., Breitman, M. L., and Kerbel, R. S. (1987) Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236, 582-585
12. Ito, Y., Miyoshi, E., Sakon, M., Takeda, T., Noda, K., Tsujimoto, M., Ito, S., Honda, H., Takemura, F., Wakasa, K., Monden, M., Matsuura, N., and Taniguchi, N. (2001) Elevated expression of UDP-N-acetylglucosamine: α-mannoside β1,6-N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. Int. J. Cancer 91, 631-637
13. Yanagi, M., Aoyagi, Y., Suda, T., Mita, Y., and Asakura, H. (2001) NAcetylglucosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 16, 1282-1289
14. Noda, K., Miyoshi, E., Uozumi, N., Yanagidani, S., Ikeda, Y., Gao, C., Suzuki, K., Yoshihara, H., Yoshikawa, K., Kawano, K., Hayashi, N., Hori, M., and Taniguchi, N. (1998) Gene expression of α1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of α-fetoprotein. Hepatology 28, 944-952
15. Wei, Y., Liu, D., Zhou, F., Ge, Y., Xu, J., Yun, X., Gu, J., and Jiang, J. (2008) Identification of β-1,4-galactosyltransferase I as a target gene of HBxinduced cell cycle progression of hepatoma cell. J. Hepatol. 49, 1029-1037
16. Jensen, P. H., Kolarich, D., and Packer, N. H. (2010) Mucin-type O-glycosylation-putting the pieces together. FEBS J. 277, 81-94
17. Brockhausen, I. (1999) Pathways of O-glycan biosynthesis in cancer cells. Biochim. Biophys. Acta 1473, 67-95
18. Hollingsworth, M. A., and Swanson, B. J. (2004) Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4, 45-60
19. Gerken, T. A., Jamison, O., Perrine, C. L., Collette, J. C., Moinova, H., Ravi, L., Markowitz, S. D., Shen, W., Patel, H., and Tabak, L. A. (2011) Emerging paradigms for the initiation of mucin-type protein O-glycosylation by the polypeptide GalNAc transferase family of glycosyltransferases. J. Biol. Chem. 286, 14493-14507
20. Schwientek, T., Bennett, E. P., Flores, C., Thacker, J., Hollmann, M., Reis, C. A., Behrens, J., Mandel, U., Keck, B., Schäfer, M. A., Haselmann, K., Zubarev, R., Roepstorff, P., Burchell, J. M., Taylor-Papadimitriou, J., Hollingsworth, M. A., and Clausen, H. (2002) Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and mammals. One subfamily composed of l(2)35Aa is essential in Drosophila. J. Biol. Chem. 277, 22623-22638
21. Ten Hagen, K. G., Fritz, T. A., and Tabak, L. A. (2003) All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13, 1R-16R
22. Wu, Y. M., Liu, C. H., Hu, R. H., Huang, M. J., Lee, J. J., Chen, C. H., Huang, J., Lai, H. S., Lee, P. H., Hsu, W. M., Huang, H. C., and Huang, M. C. (2011) Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 71, 7270-7279
23. Wu, Y. M., Liu, C. H., Huang, M. J., Lai, H. S., Lee, P. H., Hu, R. H., and Huang, M. C. (2013) C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res. 73, 5580-5590
24. nd Ed., p. 120, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,NY
25. Croce, C. M., and Calin, G. A. (2005) miRNAs, cancer, and stem cell division. Cell 122, 6-7
26. Gaziel-Sovran, A., Segura, M. F., Di Micco, R., Collins, M. K., Hanniford, D., Vega-Saenz de Miera, E., Rakus, J. F., Dankert, J. F., Shang, S., Kerbel, R. S., Bhardwaj, N., Shao, Y., Darvishian, F., Zavadil, J., Erlebacher, A., Mahal, L. K., Osman, I., and Hernando, E. (2011) miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 20, 104-118
27. Tian, X., Zhao, C., Zhu, H., She, W., Zhang, J., Liu, J., Li, L., Zheng, S., Wen, Y. M., and Xie, Y. (2010) Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection. J. Virol. 84, 3373-3381
28. Xu, J., Yun, X., Jiang, J., Wei, Y., Wu, Y., Zhang, W., Liu, Y., Wang, W., Wen, Y., and Gu, J. (2010) Hepatitis B virus X protein blunts senescencelike growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology 52, 142-154
29. Thomas, H., Senkel, S., Erdmann, S., Arndt, T., Turan, G., Klein-Hitpass, L., and Ryffel, G. U. (2004) Pattern of genes influenced by conditional expression of the transcription factors HNF6, HNF4α and HNF1β in a pancreatic beta-cell line. Nucleic Acids Res. 32, e150
30. Liu, H., Xu, J., Zhou, L., Yun, X., Chen, L., Wang, S., Sun, L., Wen, Y., and Gu, J. (2011) Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 71, 7547-7557
31. Xu, J., Liu, H., Chen, L., Wang, S., Zhou, L., Yun, X., Sun, L., Wen, Y., and Gu, J. (2012) Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology 143, 199-212.e194
32. Zhang, W., Zhou, Q., Xu, W., Cai, Y., Yin, Z., Gao, X., and Xiong, S. (2013) DNA-dependent activator of interferon-regulatory factors (DAI) promotes lupus nephritis by activating the calcium pathway. J. Biol. Chem. 288, 13534-13550
33. Zhang, W., Xu, W., and Xiong, S. (2010) Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J. Immunol. 184, 6465-6478
34. Zhang, W., Xu, W., and Xiong, S. (2011) Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J. Immunol. 187, 1764-1777
35. Ruan, Y., Sun, L., Hao, Y., Wang, L., Xu, J., Zhang, W., Xie, J., Guo, L., Zhou, L., Yun, X., Zhu, H., Shen, A., and Gu, J. (2012) Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J. Clin. Invest. 122, 2554-2566
36. Detre, S., Saclani Jotti, G., and Dowsett, M. (1995) A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48, 876-878
37. Fornari, F., Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Tavolari, S., Chieco, P., Negrini, M., and Bolondi, L. (2009) miR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 69, 5761-5767
38. Li, Z. Y., Xi, Y., Zhu, W. N., Zeng, C., Zhang, Z. Q., Guo, Z. C., Hao, D. L., Liu, G., Feng, L., Chen, H. Z., Chen, F., Lv, X., Liu, D. P., and Liang, C. C. (2011) Positive regulation of hepatic miR-122 expression by HNF4α. J. Hepatol. 55, 602-611
39. Blivet-Van Eggelpoël, M. J., Chettouh, H., Fartoux, L., Aoudjehane, L., Barbu, V., Rey, C., Priam, S., Housset, C., Rosmorduc, O., and Desbois-Mouthon, C. (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J. Hepatol. 57, 108-115
40. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., and Sarnow, P. (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577-1581
41. Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., and Ørum, H. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201
42. Wang, S., Qiu, L., Yan, X., Jin, W., Wang, Y., Chen, L., Wu, E., Ye, X., Gao, G. F., Wang, F., Chen, Y., Duan, Z., and Meng, S. (2012) Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1-modulated p53 activity. Hepatology 55, 730-741
43. Song, K., Han, C., Zhang, J., Lu, D., Dash, S., Feitelson, M., Lim, K., and Wu, T. (2013) Epigenetic regulation of microRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology 58, 1681-1692
44. Song, K. S., Han, C., and Wu, T. (2013) Epigenetic regulation of miR-122 by PPARγR and hepatitis B virus X protein in hepatocellular carcinoma cells. FASEB J. 27, 872.10
45. Li, C., Wang, Y., Wang, S., Wu, B., Hao, J., Fan, H., Ju, Y., Ding, Y., Chen, L., Chu, X., Liu, W., Ye, X., and Meng, S. (2013) Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J. Virol. 87, 2193-2205
46. Xu, H., He, J. H., Xiao, Z. D., Zhang, Q. Q., Chen, Y. Q., Zhou, H., and Qu, L. H. (2010) Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52, 1431-1442
47. Coulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E., and Thorgeirsson, S. S. (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526-3536
48. Hatziapostolou, M., Polytarchou, C., Aggelidou, E., Drakaki, A., Poultsides, G. A., Jaeger, S. A., Ogata, H., Karin, M., Struhl, K., Hadzopou-lou-Cladaras, M., and Iliopoulos, D. (2011) An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 147, 1233-1247
49. Xiang, W. Q., Feng, W. F., Ke, W., Sun, Z., Chen, Z., and Liu, W. (2011) Hepatitis B virus X protein stimulates IL-6 expression in hepatocytes via a MyD88-dependent pathway. J. Hepatol. 54, 26-33
50. Fan, C. G., Wang, C. M., Tian, C., Wang, Y., Li, L., Sun, W. S., Li, R. F., and Liu, Y. G. (2011) miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol. Rep. 26, 1281-1286
51. Agrawal, P., Kurcon, T., Pilobello, K. T., Rakus, J. F., Koppolu, S., Liu, Z., Batista, B. S., Eng, W. S., Hsu, K. L., Liang, Y., and Mahal, L. K. (2014) Mapping posttranscriptional regulation of the human glycome uncovers microRNA defining the glycocode. Proc. Natl. Acad. Sci. U.S.A. 111, 4338-4343
52. Kasper, B. T., Koppolu, S., and Mahal, L. K. (2014) Insights into miRNA regulation of the human glycome. Biochem. Biophys. Res. Commun. 445, 774-779
53. Bernardi, C., Soffientini, U., Piacente, F., and Tonetti, M. G. (2013) Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS One 8, e76540
54. Kahai, S., Lee, S. C., Lee, D. Y., Yang, J., Li, M., Wang, C. H., Jiang, Z., Zhang, Y., Peng, C., and Yang, B. B. (2009) MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One 4, e7535
55. Peng, R. Q., Wan, H. Y., Li, H. F., Liu, M., Li, X., and Tang, H. (2012) MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide Nacetylgalactosaminyltransferase 7. J. Biol. Chem. 287, 14301-14309
56. Shan, S. W., Fang, L., Shatseva, T., Rutnam, Z. J., Yang, X., Du, W., Lu, W. Y., Xuan, J. W., Deng, Z., and Yang, B. B. (2013) Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J. Cell Sci. 126, 1517-1530
57. Li, W., Ma, H., and Sun, J. (2014) MicroRNA34a/c function as tumor suppressors in Hep2 laryngeal carcinoma cells and may reduce GALNT7 expression. Mol. Med. Rep. 9, 1293-1298
58. Brockhausen, I. (2006) Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 7, 599-604
59. Sasaki, M., Yamato, T., and Nakanuma, Y. (1999) Expression of sialyl-Tn, Tn and T antigens in primary liver cancer. Pathol. Int. 49, 325-331
60. Cao, Y., Karsten, U., Otto, G., and Bannasch, P. (1999) Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and α2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch. 434, 503-509
61. Cheng, L., Tachibana, K., Zhang, Y., Guo Jm, Kahori Tachibana, K., Kameyama, A., Wang, H., Hiruma, T., Iwasaki, H., Togayachi, A., Kudo, T., and Narimatsu, H. (2002) Characterization of a novel human UDPGalNAc transferase, pp-GalNAc-T10. FEBS Lett. 531, 115-121
62. Bennett, E. P., Mandel, U., Clausen, H., Gerken, T. A., Fritz, T. A., and Tabak, L. A. (2012) Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22, 736-756
63. Schjoldager, K. T., and Clausen, H. (2012) Site-specific protein O-glycosylation modulates proprotein processing-deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim. Biophys. Acta 1820, 2079-2094
64. Schmitt, S., Glebe, D., Tolle, T. K., Lochnit, G., Linder, D., Geyer, R., and Gerlich, W. H. (2004) Structure of pre-S2 N- and O-linked glycans in surface proteins from different genotypes of hepatitis B virus. J. Gen. Virol. 85, 2045-2053
65. Werr, M., and Prange, R. (1998) Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J. Virol. 72, 778-782
66. Tolle, T. K., Glebe, D., Linder, M., Linder, D., Schmitt, S., Geyer, R., and Gerlich, W. H. (1998) Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J. Virol. 72, 9978-9985
67. Yang, W. H., Kim, J. E., Nam, H. W., Ju, J. W., Kim, H. S., Kim, Y. S., and Cho, J. W. (2006) Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat. Cell Biol. 8, 1074-1083
68. Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois-Mouthon, C., Rey, C., Clergue, F., Poupon, R., Barbu, V., and Rosmorduc, O. (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41, 307-314
69. Su, M. C., Lien, H. C., and Jeng, Y. M. (2005) Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett. 224, 117-121
70. Bishayee, S. (2000) Role of conformational alteration in the epidermal growth factor receptor (EGFR) function. Biochem. Pharmacol. 60, 1217-1223
71. Bozkaya, G., Korhan, P., Cokakli, M., Erdal, E., Sagol, O., Karademir, S., Korch, C., and Atabey, N. (2012) Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol. Cancer 11, 64
72. Cheng, A. L., Guan, Z., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., Yang, T. S., Tak, W. Y., Pan, H., Yu, S., Xu, J., Fang, F., Zou, J., Lentini, G., Voliotis, D., and Kang, Y. K. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.Eur. J. Cancer48, 1452-1465
73. Villanueva, A., and Llovet, J. M. (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410-1426
74. Huang, S., Benavente, S., Armstrong, E. A., Li, C., Wheeler, D. L., and Harari, P. M. (2011) p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res. 71, 7071-7079
75. Asghar, U., and Meyer, T. (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J. Hepatol. 56, 686-695